Lupin receives USFDA’s approval for Carbidopa Tablets

25 Oct 2017 Evaluate

Lupin has received final approval for its Carbidopa Tablets, 25 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Aton Pharma, Inc.’s Lodosyn Tablets, 25 mg. Carbidopa Tablets, 25 mg had annual sales of approximately $21.9 million in the US, as per IMS MAT June 2017.

Lupin’s Carbidopa Tablets, 25 mg is the AB rated generic equivalent of Aton Pharma, Inc.’s Lodosyn Tablets, 25 mg. It is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2071.35 -26.30 (-1.25%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×